Revenue has been effectively absent in most recent quarters while operating margin deteriorated to -185.6% in 2024Q4 and R&D intensity dominated a cost base reaching $63.9M per quarter, suggesting expense growth is not being offset by any top-line contribution.
Zentalis Pharmaceuticals, Inc. (ZNTL) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 0 | 0 | 67.42M | 0 | 0 | 0 | 0 | 0 | 14K |
| Revenue Growth % | -100% | -100% | - | - | - | - | - | -100% | - |
| Cost of Goods Sold | 151K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -151K | 0 | 67.42M | 0 | 0 | 0 | 0 | 0 | 14K |
| Gross Margin % | - | - | 100% | - | - | - | - | - | 100% |
| Gross Profit Growth % | - | -100% | - | - | - | - | - | -100% | - |
| Operating Expenses | 150.64M | 152.81M | 258.62M | 299.51M | 227.29M | 216.54M | 118.79M | 46.84M | 23.8M |
| OpEx % of Revenue | - | - | 383.57% | - | - | - | - | - | 169978.57% |
| Selling, General & Admin | 34.94M | 37.72M | 87.11M | 59.4M | 54.55M | 40.94M | 33.89M | 8.46M | 4.88M |
| SG&A % of Revenue | - | - | 129.2% | - | - | - | - | - | 34828.57% |
| Research & Development | 115.7M | 107.3M | 167.77M | 235.16M | 172.73M | 175.6M | 84.9M | 38.39M | 18.92M |
| R&D % of Revenue | - | - | 248.82% | - | - | - | - | - | 135150% |
| Other Operating Expenses | 0 | 7.8M | 3.74M | 4.95M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -150.79M | -152.81M | -191.19M | -299.51M | -227.29M | -216.54M | -118.79M | -46.84M | -23.78M |
| Operating Margin % | - | - | -283.57% | - | - | - | - | - | -169878.57% |
| Operating Income Growth % | - | 20.08% | 36.16% | -31.78% | -4.96% | -82.29% | -153.57% | -96.97% | - |
| EBITDA | -150.18M | -152.07M | -189.91M | -298.12M | -225.86M | -216M | -118.63M | -46.73M | -23.73M |
| EBITDA Margin % | - | - | -281.65% | - | - | - | - | - | -169514.29% |
| EBITDA Growth % | 8.63% | 19.92% | 36.3% | -31.99% | -4.57% | -82.08% | -153.83% | -96.92% | - |
| D&A (Non-Cash Add-back) | 613K | 739K | 1.29M | 1.39M | 1.43M | 544K | 160K | 111K | 51K |
| EBIT | -140.85M | -145.01M | -187.46M | -248.99M | -235.01M | -207.74M | -118.79M | -46.84M | -23.78M |
| Net Interest Income | 0 | 0 | 0 | 0 | -2.57M | 0 | 0 | 498K | 355K |
| Interest Income | 0 | 0 | 0 | 0 | 2.26K | 0 | 0 | 498K | 355K |
| Interest Expense | 0 | 0 | 0 | 0 | 2.58M | 0 | 0 | 0 | 0 |
| Other Income/Expense | 9.94M | 16.19M | 25.5M | 6.6M | -10.29M | 50.15M | 683K | 482K | 355K |
| Pretax Income | -140.85M | -136.62M | -165.69M | -292.91M | -237.58M | -166.39M | -118.1M | -46.36M | -23.43M |
| Pretax Margin % | - | - | -245.74% | - | - | - | - | - | -167342.86% |
| Income Tax | 818K | 442K | 177K | -601K | -469K | -297K | 444K | 15K | 4K |
| Effective Tax Rate % | -0.58% | -0.32% | -0.11% | 0.21% | 0.2% | 0.18% | -0.38% | -0.03% | -0.02% |
| Net Income | -141.67M | -137.06M | -165.84M | -292.19M | -236.81M | -158.72M | -117.84M | -45.66M | -21.07M |
| Net Margin % | - | - | -245.96% | - | - | - | - | - | -150478.57% |
| Net Income Growth % | 5.12% | 17.35% | 43.24% | -23.39% | -49.19% | -34.69% | -158.07% | -116.75% | - |
| Net Income (Continuing) | -141.67M | -137.06M | -165.87M | -292.31M | -237.11M | -166.09M | -118.55M | -46.38M | -23.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 107K | 221K | 528K | 24.8M | 6.82M | 7.54M |
| EPS (Diluted) | -1.67 | -1.91 | -2.33 | -4.47 | -4.48 | -3.72 | -2.87 | -1.29 | -1.17 |
| EPS Growth % | 7.69% | 18.03% | 47.87% | 0.22% | -20.43% | -29.62% | -122.48% | -10.26% | - |
| EPS (Basic) | - | -1.91 | -2.33 | -4.47 | -4.48 | -3.72 | -2.87 | -1.29 | -1.17 |
| Diluted Shares Outstanding | 84.61M | 71.87M | 71.08M | 65.41M | 52.86M | 42.69M | 41.04M | 35.88M | 18.06M |
| Basic Shares Outstanding | 84.61M | 71.87M | 71.08M | 65.41M | 52.86M | 42.69M | 41.04M | 35.88M | 18.06M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ZNTL stock.
For fiscal year 2025, Zentalis Pharmaceuticals, Inc. (ZNTL) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.0M in 2018.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $137.1M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Sustained operating losses with no revenue
Metrics are mathematically derived from official filings.
Revenue Stream Essentially Absent Recently
Based on the supplied quarterly income statement data, ZNTL reported revenue of $40.6M in 2024Q1 and $26.9M in 2024Q4, with no reported revenue in the intervening and subsequent quarters, making top-line trajectory difficult to assess.
The revenue line is sporadic and lumpy rather than recurring, which suggests reliance on collaboration, licensing, or milestone receipts rather than a commercial product base. Given that most quarters show zero revenue, growth-rate metrics are not meaningful, and investors should monitor whether any future revenue is recurring or one-time in nature. The absence of a stable revenue base warrants further investigation into the timing and durability of any future receipts.
Operating Losses Persist Despite Cost Controls
As reported in the quarterly figures, ZNTL's operating loss widened to -$82.2M in 2026Q2 from -$37.9M in 2026Q1, with R&D rising to $63.9M, indicating expense growth outpacing any revenue offset.
Operating income has remained negative across all ten reported quarters, meaning there is no evident operating leverage to date since there is little gross profit to scale against. The R&D line is the dominant cost driver, and its sharp increase in the most recent quarter suggests a deliberate step-up in clinical spending that may indicate pipeline advancement but also raises the cash consumption burden. SG&A has fluctuated materially, which may reflect timing effects rather than structural efficiency gains.
Net Losses Dominated by Operating Expense
Based on reported figures, ZNTL's EPS swung from a positive $0.14 in 2024Q1 to a loss of -$1.10 in 2026Q2, while stock-based compensation reached $31.4M in 2024Q4, a significant non-cash component.
The positive 2024Q1 net income appears to reflect a one-off revenue recognition rather than sustainable profitability, as subsequent quarters returned to losses. Stock-based compensation is a material non-cash charge that inflates the apparent operating burden relative to cash spending, though the R&D and SG&A lines still represent real economic costs. The large EPS volatility suggests net results are heavily influenced by lumpy revenue and non-operating timing rather than an underlying earnings trend.
R&D Intensity Defines the Cost Structure
Per the supplied income statement, R&D expense ranged from $22.9M to $63.9M per quarter across the period, representing the predominant operating cost and effectively all of the company's cost base in most periods.
The cost structure is clearly weighted toward research and development, which is typical of clinical-stage biotechnology but means expense discipline is best judged through R&D trajectory relative to clinical milestones. SG&A has been comparatively modest but volatile, moving between roughly $7M and $40M per quarter. Investors should monitor whether R&D spending translates into pipeline progress that justifies the continued burn rate.
Burn Rate and Dilution Risk Loom
Based on the reported quarterly losses, ZNTL's most recent net loss of -$77.6M against a backdrop of no reported revenue suggests the company may depend on external capital, which could pressure per-share economics through dilution.
The bear case centers on the persistence of losses and the lack of a visible revenue base, which could leave the company reliant on equity or debt financing if it cannot fund operations internally. The sharp acceleration in quarterly net loss from prior periods warrants scrutiny of cash runway, though the supplied income statement alone does not establish financing access or liquidity position. Investors should treat the absence of profitability as a material analytical concern until revenue becomes recurring.